constructed a peptide‐assembled nanostructure known as NIA‐LLPLGLAG‐D1, which included the MMP‐2‐responsive peptide PLGLAG, the radiosensitizer 2‐(2‐nitroimidazol‐1‐yl) acetic acid (NIA), and the PD‐L1 antagonist D1.[132] With the help of PLGLAG, NIA‐LLPLGLAG‐D1 can be effectively enriched at tumor sites and selectively release NIA, ultimately improving tumor radiation sensitivity and activating the immunological system. This evidence concerns the gene CD274 and neoplasm.